USF3

Summary

USF3 (upstream transcription factor family member 3, HGNC:30494) is a protein-coding gene on chromosome 3q13.2, encoding Basic helix-loop-helix domain-containing protein USF3 (Q68DE3). Involved in the negative regulation of epithelial-mesenchymal transition, the process by which epithelial cells lose their polarity and adhesion properties to become mesenchymal cells with enhanced migration and invasive properties.

This gene encodes a large protein that contains a helix-loop-helix domain and a polyglutamine region. A deletion in the polyglutamine region was associated with risk for thyroid carcinoma.

Source: NCBI Gene 205717 — RefSeq curated summary.

At a glance

• Gene–disease (curated): Cowden disease (Supportive, GenCC) — +1 more curated relationship
• GWAS associations: 6
• Clinical variants (ClinVar): 295 total
• Phenotypes (HPO): 57
• MANE Select transcript: NM_001009899

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:30494
Approved symbol	USF3
Name	upstream transcription factor family member 3
Location	3q13.2
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000176542
Ensembl biotype	protein_coding
OMIM	617568
Entrez	205717

Gene structure

Transcript identifiers

Ensembl transcripts: 4 — 3 protein_coding, 1 retained_intron

ENST00000316407, ENST00000478658, ENST00000491165, ENST00000496826

RefSeq mRNA: 1 — MANE Select: NM_001009899 NM_001009899

CCDS: CCDS43133

Canonical transcript exons

ENST00000316407 — 7 exons

Exon	Start	End
ENSE00001255501	113648385	113661425
ENSE00001532131	113677282	113677397
ENSE00003511411	113664313	113664409
ENSE00003844447	113696370	113696642
ENSE00003890030	113670121	113670203
ENSE00003893718	113674832	113674896
ENSE00003894946	113673348	113673376

Expression profiles

Bgee: expression breadth ubiquitous, 254 present calls, max score 96.20.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 4.9992 / max 198.0316, expressed in 1544 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
43850	4.9992	1544

Top tissues by expression

256 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
kidney epithelium	UBERON:0004819	96.20	gold quality
deltoid	UBERON:0001476	94.57	gold quality
tibialis anterior	UBERON:0001385	93.12	gold quality
vastus lateralis	UBERON:0001379	92.99	gold quality
pancreatic ductal cell	CL:0002079	92.93	silver quality
quadriceps femoris	UBERON:0001377	92.66	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	91.61	gold quality
skeletal muscle tissue	UBERON:0001134	91.27	gold quality
biceps brachii	UBERON:0001507	91.24	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	89.58	gold quality
nipple	UBERON:0002030	89.24	gold quality
jejunal mucosa	UBERON:0000399	89.09	gold quality
muscle tissue	UBERON:0002385	89.03	gold quality
upper arm skin	UBERON:0004263	88.99	gold quality
jejunum	UBERON:0002115	88.83	gold quality
superior surface of tongue	UBERON:0007371	88.38	gold quality
sperm	CL:0000019	88.28	gold quality
renal medulla	UBERON:0000362	87.88	gold quality
palpebral conjunctiva	UBERON:0001812	87.68	gold quality
oviduct epithelium	UBERON:0004804	87.59	gold quality
body of tongue	UBERON:0011876	87.57	gold quality
cerebellar vermis	UBERON:0004720	87.50	gold quality
tongue	UBERON:0001723	87.36	gold quality
visceral pleura	UBERON:0002401	87.02	gold quality
esophagus squamous epithelium	UBERON:0006920	86.80	gold quality
thymus	UBERON:0002370	86.59	gold quality
Brodmann (1909) area 23	UBERON:0013554	86.41	gold quality
ileal mucosa	UBERON:0000331	86.06	gold quality
buccal mucosa cell	CL:0002336	85.73	gold quality
cardia of stomach	UBERON:0001162	85.38	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	6.04

Regulation

Is transcription factor: yes

JASPAR motifs

Motif	Name	Family
MA2601.1	USF3	bHLH-ZIP

JASPAR matrix evidence (PMIDs): PMID:39605368

miRNA regulators (miRDB)

327 targeting USF3, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-513A-5P	100.00	69.77	2465
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-429	100.00	73.44	2698
HSA-MIR-450A-1-3P	100.00	69.33	1837
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-3924	100.00	72.09	2394
HSA-MIR-200B-3P	100.00	73.31	2693
HSA-MIR-200C-3P	100.00	73.35	2685
HSA-MIR-4673	100.00	66.64	1490
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-548AW	99.99	72.57	3559
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-6077	99.99	68.04	2299
HSA-MIR-511-3P	99.99	68.85	1467
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882

Literature-anchored findings (GeneRIF, showing 3)

• Therefore, USF3 may be involved in the predisposition of thyroid cancer. Importantly, the results that glutamine-dependent survival and sensitivity to ER stress in USF3-deficient cells provide avenues for therapeutic and adjunct preventive interventions for both sporadic cancer as well as cancer predisposition syndromes with similar mechanisms. (PMID:28011713)
• Osteoporosis genome-wide association study variant c.3781 C>A is regulated by a novel anti-osteogenic factor miR-345-5p. (PMID:31883164)
• USF3 modulates osteoporosis risk by targeting WNT16, RANKL, RUNX2, and two GWAS lead SNPs rs2908007 and rs4531631. (PMID:33058301)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	usf3	ENSDARG00000077431
mus_musculus	Usf3	ENSMUSG00000068284
rattus_norvegicus	Usf3	ENSRNOG00000027756

Protein

Protein identifiers

Basic helix-loop-helix domain-containing protein USF3 — Q68DE3 (reviewed: Q68DE3)

Alternative names: Upstream transcription factor 3

All UniProt accessions (2): C9JBW0, Q68DE3

UniProt curated annotations — full annotation on UniProt →

Function. Involved in the negative regulation of epithelial-mesenchymal transition, the process by which epithelial cells lose their polarity and adhesion properties to become mesenchymal cells with enhanced migration and invasive properties.

Subcellular location. Nucleus.

RefSeq proteins (1): NP_001009899* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR011598	bHLH_dom	Domain
IPR036638	HLH_DNA-bd_sf	Homologous_superfamily
IPR048064	USF3_bHLH	Domain
IPR053252	EMT_regulator	Family

Pfam: PF00010

UniProt features (45 total): compositionally biased region 15, region of interest 14, sequence variant 7, sequence conflict 6, chain 1, domain 1, coiled-coil region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q68DE3-F1	36.98	0.04

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 308 (showing top): GOBP_NEGATIVE_REGULATION_OF_EPITHELIAL_TO_MESENCHYMAL_TRANSITION, GOBP_NEGATIVE_REGULATION_OF_MULTICELLULAR_ORGANISMAL_PROCESS, GOBP_MESENCHYMAL_CELL_DIFFERENTIATION, GOBP_NEGATIVE_REGULATION_OF_DEVELOPMENTAL_PROCESS, GOBP_MESENCHYME_DEVELOPMENT, TAATGTG_MIR323, GOBP_REGULATION_OF_EPITHELIAL_TO_MESENCHYMAL_TRANSITION, DURCHDEWALD_SKIN_CARCINOGENESIS_DN, ZHENG_BOUND_BY_FOXP3, GOMF_PROTEIN_DIMERIZATION_ACTIVITY, NUYTTEN_NIPP1_TARGETS_DN, ZHOU_INFLAMMATORY_RESPONSE_LIVE_UP, GOMF_SEQUENCE_SPECIFIC_DNA_BINDING, DODD_NASOPHARYNGEAL_CARCINOMA_DN, LEE_DIFFERENTIATING_T_LYMPHOCYTE

GO Biological Process (2): negative regulation of epithelial to mesenchymal transition (GO:0010719), positive regulation of transcription by RNA polymerase II (GO:0045944)

GO Molecular Function (4): RNA polymerase II transcription regulatory region sequence-specific DNA binding (GO:0000977), DNA-binding transcription activator activity, RNA polymerase II-specific (GO:0001228), protein dimerization activity (GO:0046983), DNA binding (GO:0003677)

GO Cellular Component (1): nucleus (GO:0005634)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
epithelial to mesenchymal transition	1
regulation of epithelial to mesenchymal transition	1
negative regulation of cell differentiation	1
negative regulation of multicellular organismal process	1
regulation of transcription by RNA polymerase II	1
transcription by RNA polymerase II	1
positive regulation of DNA-templated transcription	1
transcription cis-regulatory region binding	1
RNA polymerase II transcription regulatory region sequence-specific DNA binding	1
DNA-binding transcription factor activity, RNA polymerase II-specific	1
DNA-binding transcription activator activity	1
positive regulation of transcription by RNA polymerase II	1
protein binding	1
nucleic acid binding	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

1150 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
USF3	ASTE1	Q2TB18	513
USF3	CCDC150	Q8NCX0	455
USF3	TMEM244	Q5VVB8	447
USF3	ANKAR	Q7Z5J8	447
USF3	CAPN12	Q6ZSI9	433
USF3	SEC23B	Q15437	420
USF3	LRTM3	Q8NDH2	397
USF3	KLLN	B2CW77	395
USF3	MRPL34	Q9BQ48	388
USF3	EBLN2	Q6P2I7	377
USF3	ADGRG7	Q96K78	375
USF3	MRPS14	O60783	371
USF3	C9orf43	Q8TAL5	370
USF3	OR11G2	Q8NGC1	367
USF3	MRPL48	Q96GC5	364

IntAct

17 interactions, top by confidence:

A	B	Type	Score
TSG101	USF3	psi-mi:“MI:0407”(direct interaction)	0.440
USF3	H1-2	psi-mi:“MI:0915”(physical association)	0.400
USF3	HIST2H2BF	psi-mi:“MI:0915”(physical association)	0.400
USF3	H4C16	psi-mi:“MI:0915”(physical association)	0.400
USF3	H3-4	psi-mi:“MI:0915”(physical association)	0.400
USF3	H2BC9	psi-mi:“MI:0915”(physical association)	0.400
USF3	H2BC21	psi-mi:“MI:0915”(physical association)	0.400
USF3	H2BC5	psi-mi:“MI:0915”(physical association)	0.400
USF3	HMGN2	psi-mi:“MI:0915”(physical association)	0.400
USF3	H2BC12L	psi-mi:“MI:0915”(physical association)	0.400
USF3	H2AC4	psi-mi:“MI:0915”(physical association)	0.400
USF3	SDHA	psi-mi:“MI:0915”(physical association)	0.400
SDC2	ELAPOR2	psi-mi:“MI:0914”(association)	0.350
USF3		psi-mi:“MI:0915”(physical association)	0.000
USF3	NFYC	psi-mi:“MI:0915”(physical association)	0.000

ESM2 similar proteins: A0A1L8GSA2, A0A1L8H0H2, A0JN51, A0JP82, A2AWL7, A2BGM5, A2RRX6, F8VPJ6, K9JHZ4, O13186, O46567, O54826, O89091, P04150, P08235, P15822, P22199, P32519, P36197, P37275, P48552, P55197, P59759, P79269, P79686, Q29131, Q2KHR2, Q3YC04, Q4JM28, Q5R9P5, Q60775, Q61321, Q62947, Q64318, Q68DE3, Q6XLJ0, Q8AYC1, Q8AYC2, Q8BMA5, Q8IZQ8

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 15 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Packaging Of Telomere Ends	7	128.1×	2e-12
Recognition and association of DNA glycosylase with site containing an affected purine	7	119.0×	2e-12
Cleavage of the damaged purine	7	119.0×	2e-12
Replacement of protamines by nucleosomes in the male pronucleus	5	113.3×	1e-09
Recognition and association of DNA glycosylase with site containing an affected pyrimidine	7	107.5×	2e-12
Cleavage of the damaged pyrimidine	7	107.5×	2e-12
Inhibition of DNA recombination at telomere	7	98.0×	3e-12
DNA Damage/Telomere Stress Induced Senescence	7	95.2×	3e-12

GO biological processes:

GO term	Partners	Fold	FDR
nucleosome assembly	5	54.0×	1e-06

Disease & clinical

Clinical variants and AI predictions

ClinVar

295 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	252
Likely benign	20
Benign	5

Top pathogenic / likely-pathogenic (0)

SpliceAI

846 predictions. Top by Δscore:

Variant	Effect	Δscore
3:113661426:C:CC	acceptor_gain	1.0000
3:113664307:CTTTA:C	donor_loss	1.0000
3:113664308:TTTAC:T	donor_loss	1.0000
3:113664309:TTACC:T	donor_loss	1.0000
3:113664310:TAC:T	donor_loss	1.0000
3:113664408:CT:C	acceptor_gain	1.0000
3:113664409:TCTG:T	acceptor_loss	1.0000
3:113664410:C:CC	acceptor_gain	1.0000
3:113664415:C:CT	acceptor_gain	1.0000
3:113664415:C:T	acceptor_gain	1.0000
3:113664416:A:T	acceptor_gain	1.0000
3:113674827:CATA:C	donor_loss	1.0000
3:113674828:ATAC:A	donor_loss	1.0000
3:113674829:TACC:T	donor_loss	1.0000
3:113674830:A:T	donor_loss	1.0000
3:113674831:C:G	donor_loss	1.0000
3:113674894:AACC:A	acceptor_loss	1.0000
3:113674897:C:CA	acceptor_loss	1.0000
3:113674897:C:CC	acceptor_gain	1.0000
3:113674898:T:A	acceptor_loss	1.0000
3:113696366:TTA:T	donor_loss	1.0000
3:113696367:TA:T	donor_loss	1.0000
3:113696368:A:AC	donor_gain	1.0000
3:113696368:AC:A	donor_gain	1.0000
3:113696368:ACCCG:A	donor_gain	1.0000
3:113696369:C:CT	donor_gain	1.0000
3:113696369:CC:C	donor_gain	1.0000
3:113696369:CCCG:C	donor_gain	1.0000
3:113696369:CCCGC:C	donor_gain	1.0000
3:113661423:CAG:C	acceptor_gain	0.9900

AlphaMissense

14783 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
3:113661353:A:G	L110P	1.000
3:113664384:G:T	A62D	1.000
3:113664385:C:G	A62P	1.000
3:113664393:A:G	L59P	1.000
3:113664396:A:C	I58S	1.000
3:113664396:A:T	I58N	1.000
3:113664404:C:A	K55N	1.000
3:113664404:C:G	K55N	1.000
3:113664405:T:A	K55M	1.000
3:113670149:A:G	L44P	1.000
3:113670167:A:T	I38K	1.000
3:113670171:C:G	G37R	1.000
3:113670171:C:T	G37R	1.000
3:113670174:C:G	A36P	1.000
3:113670179:A:C	I34S	1.000
3:113670179:A:G	I34T	1.000
3:113670179:A:T	I34N	1.000
3:113670187:C:A	K31N	1.000
3:113670187:C:G	K31N	1.000
3:113670189:T:C	K31E	1.000
3:113670190:T:A	R30S	1.000
3:113670190:T:G	R30S	1.000
3:113670191:C:A	R30I	1.000
3:113670191:C:G	R30T	1.000
3:113670192:T:C	R30G	1.000
3:113670196:C:A	R28S	1.000
3:113670196:C:G	R28S	1.000
3:113670200:T:A	E27V	1.000
3:113670201:C:T	E27K	1.000
3:113673357:G:C	H23D	1.000

dbSNP variants (sampled 300 via entrez): RS1000001993 (3:113652044 T>C), RS1000089700 (3:113673651 A>G), RS1000247099 (3:113668201 G>A), RS1000263389 (3:113692222 C>T), RS1000445900 (3:113685312 A>G), RS1000451040 (3:113660522 C>T), RS1000522289 (3:113693852 T>C), RS1000557481 (3:113659559 A>G,T), RS1000559004 (3:113652808 T>C,G), RS1000578511 (3:113678881 A>C), RS1000688986 (3:113671949 C>T), RS1000694547 (3:113679071 C>G,T), RS1000864202 (3:113665146 G>A), RS1001110138 (3:113673962 A>G), RS1001162417 (3:113657734 G>A)

Disease associations

OMIM: gene MIM:617568 | disease phenotypes: MIM:158350

GenCC curated gene-disease

Disease	Classification	Inheritance
Cowden disease	Supportive	Autosomal dominant
schizophrenia	No Known Disease Relationship	Unknown

Mondo (3): Cowden disease (MONDO:0016063), CIC-rearranged sarcoma (MONDO:0956989), schizophrenia (MONDO:0005090)

Orphanet (1): Cowden syndrome (Orphanet:201)

HPO phenotypes

57 total (30 of 57 shown, HPO-id order):

HPO	Term
HP:0000036	Abnormal penis morphology
HP:0000077	Abnormality of the kidney
HP:0000130	Abnormality of the uterus
HP:0000158	Macroglossia
HP:0000218	High palate
HP:0000221	Furrowed tongue
HP:0000256	Macrocephaly
HP:0000365	Hearing impairment
HP:0000518	Cataract
HP:0000545	Myopia
HP:0000717	Autism
HP:0000767	Pectus excavatum
HP:0000771	Gynecomastia
HP:0000820	Abnormality of the thyroid gland
HP:0000853	Goiter
HP:0000982	Palmoplantar keratoderma
HP:0000995	Melanocytic nevus
HP:0001048	Cavernous hemangioma
HP:0001053	Hypopigmented skin patches
HP:0001156	Brachydactyly
HP:0001249	Intellectual disability
HP:0001250	Seizure
HP:0001251	Ataxia
HP:0001263	Global developmental delay
HP:0001317	Abnormal cerebellum morphology
HP:0001482	Subcutaneous nodule
HP:0001508	Failure to thrive
HP:0002516	Increased intracranial pressure
HP:0002650	Scoliosis
HP:0002664	Neoplasm

GWAS associations

6 associations (top):

Study	Trait	p-value
GCST001942_7	Prostate cancer	4.000000e-13
GCST007691_1	Femoral neck bone mineral density	4.000000e-10
GCST008152_48	Weight	1.000000e-06
GCST008158_45	Body mass index	1.000000e-06
GCST008363_106	Offspring birth weight	1.000000e-08
GCST009391_1132	Metabolite levels	6.000000e-06

EFO canonical traits (6, from GWAS)

EFO ID	Trait name
EFO:0007785	femoral neck bone mineral density
EFO:0004338	body weight
EFO:0004340	body mass index
EFO:0004344	birth weight
EFO:0005939	parental genotype effect measurement
EFO:0010489	glycerophosphocholine measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D006223	Hamartoma Syndrome, Multiple	C04.445.435; C04.651.435; C04.700.435; C16.320.700.435

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

21 total (human), top 21 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	increases expression, decreases expression, increases methylation, affects cotreatment	4
Aflatoxin B1	decreases methylation, increases methylation, decreases expression	3
Acetaminophen	decreases expression	2
Benzo(a)pyrene	affects methylation, increases mutagenesis	2
dicrotophos	increases expression	1
triphenyl phosphate	affects expression	1
2-butenal	decreases expression	1
butyraldehyde	decreases expression	1
di-n-butylphosphoric acid	affects expression	1
abrine	decreases expression	1
Grape Seed Proanthocyanidins	affects cotreatment, increases expression	1
jinfukang	decreases expression	1
Arsenic	affects methylation	1
Catechin	affects cotreatment, increases expression	1
Cisplatin	decreases expression	1
Hydralazine	affects cotreatment, increases expression	1
Phthalic Acids	increases methylation	1
Tretinoin	increases expression	1
Urethane	increases expression	1
Antirheumatic Agents	increases expression	1
Lactic Acid	decreases expression	1

Clinical trials (associated diseases)

316 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00000374	PHASE4	COMPLETED	Treatment for First-Episode Schizophrenia
NCT00001656	PHASE4	COMPLETED	Comparison of Clozapine vs Olanzapine in Childhood-Onset Psychotic Disorders
NCT00007774	PHASE4	COMPLETED	To Determine if Olanzapine is More Cost Effective Than Haloperidol for the Treatment of Schizophrenia
NCT00014001	PHASE4	COMPLETED	CATIE- Schizophrenia Trial
NCT00018668	PHASE4	COMPLETED	Antipsychotic Response in Schizophrenia
NCT00034801	PHASE4	COMPLETED	Olanzapine Versus Active Comparator in the Treatment of Depression in Patients With Schizophrenia
NCT00034905	PHASE4	COMPLETED	A Comparison of Seroquel vs. Risperidone in Schizophrenia
NCT00036088	PHASE4	COMPLETED	Olanzapine Versus An Active Comparator in the Treatment of Schizophrenia
NCT00044187	PHASE4	COMPLETED	The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder
NCT00044655	PHASE4	COMPLETED	Switching Medication to Treat Schizophrenia
NCT00048828	PHASE4	COMPLETED	Treating Drug-Resistant Childhood Schizophrenia
NCT00053703	PHASE4	COMPLETED	Treatment of Early Onset Schizophrenia Spectrum Disorders (TEOSS)
NCT00056498	PHASE4	COMPLETED	Risperidone Treatment in Schizophrenia Patients Who Are Currently Taking Clozapine
NCT00061802	PHASE4	COMPLETED	Efficacy and Safety of Two Atypical Antipsychotics vs. Placebo in Patients With an Acute Exacerbation of Either Schizophrenia or Schizoaffective Disorder
NCT00080327	PHASE4	COMPLETED	Study of Three Doses of Aripiprazole in Patients With Acute Schizophrenia
NCT00088049	PHASE4	COMPLETED	Study of Olanzapine vs. Aripiprazole in the Treatment of Schizophrenia
NCT00090012	PHASE4	COMPLETED	Comparison of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective Disorder
NCT00100776	PHASE4	COMPLETED	Efficacy of High Dose Olanzapine for the Treatment of Schizophrenia and Schizoaffective Disorder
NCT00103571	PHASE4	COMPLETED	Olanzapine Versus Aripiprazole in the Treatment of Acutely Ill Patients With Schizophrenia
NCT00108368	PHASE4	COMPLETED	The Effects of Risperidone and Olanzapine on Thinking
NCT00114595	PHASE4	COMPLETED	Ethyl-Eicosapentaenoic Acid and Tardive Dyskinesia
NCT00130923	PHASE4	COMPLETED	Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder
NCT00137020	PHASE4	COMPLETED	Clinical Effect Of Cross Titration Of Antipsychotics With Ziprasidone In Schizophrenia Or Schizoaffective Disorder
NCT00140166	PHASE4	COMPLETED	Treatment of Acute Schizophrenia With Vitamin Therapy
NCT00145847	PHASE4	COMPLETED	Naltrexone Treatment of Alcohol Abuse in Schizophrenia
NCT00148564	PHASE4	COMPLETED	Energy Homeostasis Under Treatment With Atypical Antipsychotics
NCT00156715	PHASE4	COMPLETED	Efficacy of Quetiapine in the Treatment of Patients With Schizophrenia and a Comorbid Substance Use Disorder
NCT00158223	PHASE4	COMPLETED	Effectiveness of Pimozide in Augmenting the Effects of Clozapine in the Treatment of Schizophrenia
NCT00159081	PHASE4	COMPLETED	One Year Drug Treatment in First-Episode Schizophrenia
NCT00159120	PHASE4	COMPLETED	Maintenance Treatment vs. Stepwise Drug Discontinuation in First-Episode Schizophrenia
NCT00159133	PHASE4	COMPLETED	Prodrome-Based Early Intervention With Antipsychotics vs. Benzodiazepines in First-Episode Schizophrenia
NCT00159757	PHASE4	TERMINATED	12 Week Open, Non-Comparative Switch Study Of Oral Ziprazidone In Previously Treated Schizophrenic Patients
NCT00167817	PHASE4	COMPLETED	Effect of Switch to Aripiprazole on Health and Smoking Parameters in Patients With Schizophrenia: A Pilot Study
NCT00169026	PHASE4	TERMINATED	Alcoholism and Schizophrenia: Effects of Clozapine
NCT00169039	PHASE4	TERMINATED	Clozapine Versus Chlorpromazine for Treatment-Unresponsive Schizophrenia
NCT00169065	PHASE4	COMPLETED	Effectiveness of Clozapine Versus Olanzapine for Treatment-resistant Schizophrenia
NCT00169091	PHASE4	TERMINATED	Clozapine Versus Haloperidol for Treating the First Episode of Schizophrenia
NCT00176423	PHASE4	COMPLETED	Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia
NCT00176436	PHASE4	COMPLETED	Atomoxetine for Treatment of Weight Gain in Olanzapine or Clozapine Patients
NCT00177008	PHASE4	COMPLETED	Aripiprazole for the Treatment of Schizophrenia With Co-Morbid Social Anxiety